journal
MENU ▼
Read by QxMD icon Read
search

Therapeutic Advances in Psychopharmacology

journal
https://www.readbyqxmd.com/read/28101325/role-of-psilocybin-in-the-treatment-of-depression
#1
Ananya Mahapatra, Rishi Gupta
Psilocybin is a naturally occurring alkaloid, pharmacologically similar to the classic hallucinogen lysergic acid diethylamide (LSD). Although primarily used as a recreational drug or an entheogen in particular cultural settings, recent population based studies have shown that it does not lead to serious physical or mental health problems or dependent use. In view of recent work demonstrating psilocybin's potential to increase subjective sense of wellbeing and because of its novel mechanism of 5-HT2A serotonin receptor agonism, it is being explored for possible therapeutic utility in mood and anxiety disorders...
January 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28101324/oxytocin-for-frontotemporal-dementia-a-systematic-review
#2
REVIEW
Rajesh R Tampi, Michael Maksimowski, Mohsina Ahmed, Deena J Tampi
BACKGROUND: The aim of this systematic review is to identify published randomized controlled trials (RCTs) that evaluated the use of oxytocin in individuals with frontotemporal dementia (FTD). METHODS: A literature search was conducted of PubMed, MEDLINE, EMBASE, PsycINFO and Cochrane collaboration databases for RCTs in any language that evaluated the use of oxytocin in individuals with FTD. Bibliographic databases of published articles were also searched for additional studies...
January 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28101323/gabapentin-treatment-in-clozapine-induced-restless-legs-syndrome-two-cases-and-a-review-of-the-literature
#3
REVIEW
Vijaya Kumar, Ganesan Venkatasubramanian
Restless legs syndrome (RLS) is a neuro-sensorimotor disorder affecting 2-4% of adults. It is characterized by intense urges to move the legs, associated with unpleasant sensory disturbances in the legs occurring at rest and manifests mostly in the evening and night, relieved by movement. Diagnosis is primarily based on clinical presentation and the consensus criteria for the diagnosis have been established. Antipsychotics, the dopamine antagonists, have been reported to induce RLS. Dopamine agonists, the effective first-line treatment of RLS, carry the risk of inducing or worsening psychosis...
January 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28101322/brexpiprazole-and-cariprazine-distinguishing-two-new-atypical-antipsychotics-from-the-original-dopamine-stabilizer-aripiprazole
#4
REVIEW
Joshua S Frankel, Thomas L Schwartz
BACKGROUND: Brexpiprazole and cariprazine are the latest US Food and Drug Administration approved atypical antipsychotics available in the United States. Both function as partial agonists of the dopamine-2 receptor (D2R), a mechanism of action shared with aripiprazole. However, all three differ in their affinities for the D2R as well as for serotonin receptors (5-HTRs). This paper seeks to delineate these pharmacodynamic and clinical differences amongst the three dopamine partial agonist atypical antipsychotic drugs...
January 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28101321/switching-away-from-pipotiazine-palmitate-a-naturalistic-study
#5
Feras Ali Mustafa
BACKGROUND: In March 2015, pipotiazine palmitate depot antipsychotic was globally withdrawn due to the shortage of its active ingredient. Thus, all patients receiving this medication had to be switched to an alternative antipsychotic drug. In this study we set to evaluate the process of switching away from pipotiazine palmitate within our clinical service, and its impact on hospitalization. METHODS: Demographic and clinical data on patients who were receiving pipotiazine palmitate in Northamptonshire at the time of its withdrawal were anonymously extracted from their electronic records and analyzed using descriptive statistics...
January 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28101320/variation-in-dose-and-plasma-level-of-lamotrigine-in-patients-discharged-from-a-mental-health-trust
#6
Petrina Douglas-Hall, Olubanke Dzahini, Fiona Gaughran, Ahmed Bile, David Taylor
BACKGROUND: The objectives of this study were to investigate the dose of lamotrigine when prescribed with an enzyme inhibitor or enzyme inducer in patients discharged from a mental health trust and to determine the corresponding lamotrigine plasma concentrations and the factors that may affect these. METHODS: All patients discharged on lamotrigine between October 2007 and September 2012 were identified using the pharmacy dispensing database. We recorded demographic details, lamotrigine dose and plasma levels and coprescribed medication...
January 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28101319/the-nursing-assessment-of-medication-acceptance-the-reliability-and-validity-of-a-schizophrenia-medication-adherence-scale
#7
Hikaru Hori, Nobuhisa Ueda, Hideki Shiozuka, Ryohei Igata, Tazuko Miki, Kiyokazu Atake, Yuji Takeuchi, Hiroaki Shirozu, Naotoshi Ohara, Yuki Konishi, Hiroshi Nagai, Noriaki Sakurai, Takanori Kubota, Reiji Yoshimura
BACKGROUND: Many patients with schizophrenia have low medication adherence. There is, however, no objective assessment scale that can be used by nurses or caregiver specialists. The Nursing Assessment of Medication Acceptance (NAMA) was developed to assess patients' medication adherence. The aim of this study was to examine the validity and reliability of the NAMA in patients with schizophrenia. METHODS: A total of 121 Japanese patients with schizophrenia were enrolled...
January 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28101318/prevalence-and-correlates-of-antipsychotic-polypharmacy-among-outpatients-with-schizophrenia-attending-a-tertiary-psychiatric-facility-in-nigeria
#8
Nosa Godwin Igbinomwanhia, Sunday Osasu Olotu, Bawo Onesirosan James
BACKGROUND: The study aimed to determine the prevalence, pattern and correlates of antipsychotic polypharmacy (APP) among outpatients with schizophrenia attending a tertiary psychiatric facility in Nigeria. METHOD: A cross-sectional study of 250 patients with schizophrenia attending the outpatient clinic of a regional tertiary psychiatric facility in Nigeria was undertaken. They were administered a sociodemographic questionnaire, the Positive and Negative Syndrome Scale (PANSS), the Global Assessment of Functioning (GAF) scale and the Liverpool University Side Effects Rating Scale (LUNSERS)...
January 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28008352/low-dose-quetiapine-complements-stimulant-response-in-attention-deficit-hyperactivity-disorder-and-more
#9
Ahmed Naguy
No abstract text is available yet for this article.
December 2016: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28008351/methamphetamine-addiction-potential-substitute-treatment
#10
Florence Levy
No abstract text is available yet for this article.
December 2016: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28008350/safety-profile-of-lamotrigine-in-overdose
#11
REVIEW
Akintunde Alabi, Adam Todd, Andrew Husband, Joe Reilly
BACKGROUND: Lamotrigine is an anticonvulsant as well as a mood stabilizer. Apart from its established use in the treatment of epilepsy, there has been an expansion of its use in the treatment of mental disorders. Patients with epilepsy as well as those with mental disorders are at increased risk of deliberate drug overdoses. An evidence base for the safety profile of lamotrigine in overdose is an essential tool for prescribers. The objective of this study was to carry out a narrative synthesis of the existing evidence for the safety profile of lamotrigine in overdose...
December 2016: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28008349/dosing-patterns-and-medication-adherence-in-bipolar-disorder-patients-treated-with-lurasidone-a-us-retrospective-claims-database-analysis
#12
Martha Sajatovic, Daisy Ng-Mak, Caitlyn T Solem, Fang-Ju Lin, Krithika Rajagopalan, Antony Loebel
BACKGROUND: The aim of this study was to describe dosing patterns and medication adherence among bipolar patients who initiated lurasidone in a real-world setting. METHODS: Adult bipolar patients who initiated lurasidone between 1 November 2010 and 31 December 2012 (index period) with 6-month pre- and post-index continuous enrollment were identified from the IMS RWD Adjudicated Claims US database. Patients were grouped by starting lurasidone daily dose: 20 mg (7...
December 2016: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28008348/do-doctors-agree-on-doses-of-antipsychotic-medications
#13
Johan Schill, Hans Olsson
BACKGROUND: The objective of this study was to investigate the concordance in attitudes of psychiatrists towards the doses of antipsychotics given to stable outpatients with schizophrenia and to examine the psychiatrists' estimates of equally potent doses of haloperidol and olanzapine. METHODS: We asked all 22 doctors serving at the psychiatry department of Jönköping County Hospital if they considered the combined dose of antipsychotics for 20 individual patients to be 'low', 'medium' or 'high'...
December 2016: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/27721973/evening-primrose-oil-reducing-serum-lithium-concentration
#14
Mugtaba Osman, Einas Badawi
No abstract text is available yet for this article.
October 2016: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/27721972/significant-weight-loss-following-clozapine-use-how-is-it-possible-a-case-report-and-review-of-published-cases-and-literature-relevant-to-the-subject
#15
Tongeji E Tungaraza
It has been repeatedly shown that clozapine is more efficacious than other antipsychotics in the management of treatment-resistant schizophrenia. However, clozapine is associated with a number of side effects including weight gain. Antipsychotic-induced weight gain has been linked with a number of untoward events including psychological factors such as stigma and low self-esteem, and physical factors such as metabolic syndromes and untimely death. The mechanism underlying antipsychotic (including clozapine)-induced weight gain is not clearly understood, although it is said to involve several brain areas, several neurotransmitters, neuropeptides and genetic factors...
October 2016: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/27721971/efficacy-of-atomoxetine-in-the-treatment-of-attention-deficit-hyperactivity-disorder-in-patients-with-common-comorbidities-in-children-adolescents-and-adults-a-review
#16
Shari L Hutchison, Jaswinder K Ghuman, Harinder S Ghuman, Irina Karpov, James M Schuster
Attention-deficit hyperactivity disorder (ADHD) is one of the most commonly diagnosed mental health disorders and is associated with higher incidence of comorbid oppositional or conduct, mood, anxiety, pervasive developmental, and substance-use disorders. Comorbid mental health conditions may alter the presence of symptoms and treatment of ADHD. Atomoxetine (ATX), a nonstimulant medication for the treatment of ADHD, may be prescribed for individuals with ADHD and comorbid conditions despite some risk for certain undesirable side effects and lower effectiveness for the treatment of ADHD than stimulants...
October 2016: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/27721970/effectiveness-of-rivastigmine-on-positive-negative-and-cognitive-symptoms-of-schizophrenia-a-double-blind-clinical-trial
#17
Saeed Shoja Shafti, Abbas Azizi Khoei
BACKGROUND: Several lines of evidence suggest that the cholinergic system may be disrupted in schizophrenia and so this may contribute to the cognitive impairments of schizophrenic patients. Because such deficits do not respond to neuroleptic treatment, different approaches have been done by acetylcholinesterase inhibitors (AChEIs). The objective of the present assessment was to evaluate the safety and clinical effects of rivastigmine, as an adjunctive drug, on the clinical symptoms of schizophrenia...
October 2016: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/27721969/evaluation-of-olanzapine-pamoate-depot-in-seriously-violent-males-with-schizophrenia-in-the-community
#18
John Kasinathan, Gillian Sharp, Anthony Barker
OBJECTIVES: Olanzapine is a well established treatment for schizophrenia. The olanzapine pamoate depot (long-acting injectable) formulation improves compliance and clinical trials have shown it to be effective. However, there are no previously published reports evaluating olanzapine depot in violent patients with schizophrenia in the community. We evaluated the clinical efficacy of olanzapine depot, its effect on violence, hospitalization and incarceration in community patients with schizophrenia and prior history of serious violence...
October 2016: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/27536348/new-avenues-for-treating-emotional-memory-disorders-towards-a-reconsolidation-intervention-for-posttraumatic-stress-disorder
#19
REVIEW
Merel Kindt, Arnold van Emmerik
The discovery that fear memories may change upon retrieval, a process referred to as memory reconsolidation, opened avenues to develop a revolutionary new treatment for emotional memory disorders. Reconsolidation is a two-phase process in which retrieval of a memory initiates a transient period of memory destabilization, followed by a protein synthesis-dependent restabilization phase. This reconsolidation window offers unique opportunities for amnesic agents to interfere with the process of memory restabilization, thereby weakening or even erasing the emotional expression from specific fear memories...
August 2016: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/27536347/kidney-thyroid-and-other-organ-functions-after-40-years-or-more-of-lithium-therapy-a-case-series-of-five-patients
#20
REVIEW
Agnieszka Permoda-Osip, Maria Abramowicz, Agnieszka Kraszewska, Aleksandra Suwalska, Maria Chlopocka-Wozniak, Janusz K Rybakowski
We present the cases of five patients (two men aged 64 years and 79 years) and three women (aged 64 years, 65 years and 75 years) who have received lithium treatment for 40-45 years, with particular regard to kidney and thyroid functions, hypercalcaemia and cognition, in the context of disease course and overall functioning. Lithium was initiated in the early phase of the illness (in three patients within the first 2 years). In four patients, lithium concentration was between 0.60 and 0.65 mmol/l and in one patient, between 0...
August 2016: Therapeutic Advances in Psychopharmacology
journal
journal
43489
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"